Sclareol protected against intestinal barrier dysfunction ameliorating Crohn's disease-like colitis via Nrf2/NF-B/MLCK signalling

CONCLUSIONS: SCL improved intestinal barrier dysfunction and alleviated CD-like colitis, possibly through modulation of Nrf2/NF-κB/MLCK signalling. In view of SCL's safety profile, there is hope that it will be useful in the clinic.PMID:38669952 | DOI:10.1016/j.intimp.2024.112140

Source: International Immunopharmacology - April 26, 2024 Category: Allergy & Immunology Authors: Lian Wang Xue Song Yueqing Zhou Yongsheng Xia Zi Yang Xiaohua Chen Ruohan Shi Zhijun Geng Xiaofeng Zhang Yueyue Wang Jing Li Jianguo Hu Lugen Zuo Source Type: research